Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-obstructive Hypertrophic Cardiomyopathy: early-phase trial registry
2 of 4 indexed Non-obstructive Hypertrophic Cardiomyopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Non-obstructive Hypertrophic Cardiomyopathy: 4 US clinical trials tracked, 2 recruiting.
Non-obstructive Hypertrophic Cardiomyopathy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Imbria Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition non-obstructive-hypertrophic-cardiomyopathy
OPEN 2 | RECR 50% | LATE 1 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Non-obstructive Hypertrophic Cardiomyopathy lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-obstructive Hypertrophic Cardiomyopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-obstructive Hypertrophic Cardiomyopathy is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals
NCT06481891
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals
NCT07023614
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
Imbria Pharmaceuticals
NCT04826185
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
MyoKardia
NCT03442764
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-obstructive Hypertrophic Cardiomyopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-obstructive Hypertrophic Cardiomyopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-obstructive Hypertrophic Cardiomyopathy page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Non-obstructive Hypertrophic Cardiomyopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Imbria Pharmaceuticals sponsors the most Non-obstructive Hypertrophic Cardiomyopathy trials on record, review their full trial history before evaluating a specific study. See Imbria Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-obstructive Hypertrophic Cardiomyopathy condition card totals 4 registered trials; most-linked intervention Placebo; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.